Teva Pharmaceuticals (TEVA) – Bull of the Day
Source: http://www.zacks.com/commentary/10709/Teva+Pharmaceuticals+%28TEVA%29+-+Bull+of+the+DayPosted on Monday, April 27th, 2009 | In Market Commentary, Stocks to Watch
We are initiating coverage on Teva Pharmaceuticals (TEVA) with a Buy rating and a price target of $52. We are impressed with the company’s strong performance in 2008 despite the global slowdown and are optimistic on growth prospects.
We expect Teva to continue posting strong revenues and earnings going forward thanks to new product launches, both generic and branded. We are also pleased to see Teva’s progress with its branded and biogenerics pipeline. Biogenerics should help drive growth in the long-term.
Meanwhile, the recent acquisition of Barr Pharma should help Teva strengthen its position in the U.S. and expand its presence in Europe. We believe that the current share price represents an attractive entry point for long-term investors and recommend purchase up to the $52 level.
Zacks Investment Research
Last 5 posts by Zacks Market Commentaries
- CNP & FPL Ink Pipeline Deal - Analyst Blog - November 20th, 2009
- Buffett Borrows for Rail Acquisition - Analyst Blog - November 20th, 2009
- Stone Energy Outdoes Estimates - Analyst Blog - November 20th, 2009
- Smucker's Beats, Raises Guidance - Analyst Blog - November 20th, 2009
- GameStop Meets Expectations - Analyst Blog - November 20th, 2009
barr pharma, Europe, Market Commentary, Stocks to Watch, Teva Pharmaceuticals, United States, USD, Zacks Market Commentaries
 About Zacks Market Commentaries (http://www.zacks.com/)
Zacks Market Commentaries |
No recommendations, either expressed or implied, are being made to buy, sell, hold or short any of the mentioned stocks. No legal, tax or accounting advice is expressed or implied. Always contact your attorney, CPA, or tax advisor before acting on any legal or tax issues. StraightStocks.com is not responsible for the content, products, or services of any of the advertisers on this site. StraightStocks.com receives compensation from advertisers on this blog. Services and products referred to herein are trademarks, registered trademarks, servicemarks, and/or registered servicemarks of their respective trademark or servicemark owners.